Hourglass Capital LLC Acquires 3,330 Shares of Novo Nordisk A/S (NYSE:NVO)

Hourglass Capital LLC grew its holdings in Novo Nordisk A/S (NYSE:NVO - Free Report) by 21.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 18,950 shares of the company's stock after purchasing an additional 3,330 shares during the quarter. Hourglass Capital LLC's holdings in Novo Nordisk A/S were worth $1,630,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. International Assets Investment Management LLC increased its holdings in shares of Novo Nordisk A/S by 10,608.4% in the 3rd quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company's stock valued at $215,942,000 after acquiring an additional 1,796,635 shares during the period. Mediolanum International Funds Ltd purchased a new stake in shares of Novo Nordisk A/S during the 3rd quarter worth $98,765,000. DAVENPORT & Co LLC boosted its position in shares of Novo Nordisk A/S by 75.1% during the 4th quarter. DAVENPORT & Co LLC now owns 1,052,712 shares of the company's stock worth $90,477,000 after purchasing an additional 451,641 shares in the last quarter. Wellington Management Group LLP acquired a new position in shares of Novo Nordisk A/S during the 3rd quarter worth $42,017,000. Finally, World Investment Advisors LLC raised its stake in Novo Nordisk A/S by 2,655.9% in the 3rd quarter. World Investment Advisors LLC now owns 280,409 shares of the company's stock valued at $33,388,000 after purchasing an additional 270,234 shares during the last quarter. Hedge funds and other institutional investors own 11.54% of the company's stock.

Novo Nordisk A/S Stock Up 1.3 %

Shares of Novo Nordisk A/S stock traded up $1.05 during trading on Wednesday, hitting $83.38. 5,945,118 shares of the stock traded hands, compared to its average volume of 9,213,303. The stock has a market cap of $374.18 billion, a P/E ratio of 25.34, a PEG ratio of 0.84 and a beta of 0.45. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74. Novo Nordisk A/S has a twelve month low of $77.82 and a twelve month high of $148.15. The company has a fifty day moving average price of $87.45 and a two-hundred day moving average price of $108.84.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. Equities research analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The firm also recently declared a semi-annual dividend, which will be paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st will be given a $0.7874 dividend. This is an increase from Novo Nordisk A/S's previous semi-annual dividend of $0.51. This represents a yield of 1.2%. The ex-dividend date of this dividend is Monday, March 31st. Novo Nordisk A/S's payout ratio is currently 21.88%.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the stock. UBS Group raised shares of Novo Nordisk A/S from a "sell" rating to a "buy" rating in a research note on Wednesday, January 8th. Cantor Fitzgerald reiterated an "overweight" rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. Morgan Stanley started coverage on Novo Nordisk A/S in a research note on Wednesday, February 12th. They set an "equal weight" rating for the company. Sanford C. Bernstein raised Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a research report on Monday, January 6th. Finally, BNP Paribas raised Novo Nordisk A/S to a "strong-buy" rating in a research report on Monday, December 2nd. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $145.25.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.